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ABSTRACT
EZH2 is a negative prognostic factor and is overexpressed or activated in most 
human cancers including head and neck squamous cell carcinoma (HNSCC). Analysis 
of The Cancer Genome Atlas (TCGA) HNSCC data indicated that EZH2 over-expression 
was associated with high tumor grade and conferred poor prognosis. EZH2 inhibition 
triggered cell apoptosis, cell cycle arrest and decreased cell growth in vitro. MICU1 
(mitochondrial calcium uptake1) was shown to be down regulated when EZH2 
expression was inhibited in HNSCC. When the EZH2 and MICU1 were inhibited, HNSCC 
cells became susceptible to cell cycle arrest and apoptosis. Mitochondrial membrane 
potential and cytosolic Ca2+ concentration analysis suggested that EZH2 and MICU1 
were required to maintain mitochondrial membrane potential stability. A xenograft 
tumor model was used to confirm that EZH2 depletion inhibited HNSCC cell growth 
and induced tumor cell apoptosis. In summary, EZH2 is a potential anti-tumor target 
in HNSCC.
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) 
is the six common cancers of human beings [1]. Although 
a systemic treatment strategy is practiced in treating the 
patients with HNSCC, the overall survival remains low 
[2-4]. There is an urgent need to better understand the 
molecular mechanism and find a more affective molecular 
target with diagnosis and therapeutic potential in HNSCC. 
Enhancer of zeste homolog 2 (EZH2), a catalytic 
component of Polycomb repressive complex 2 (PRC2), 
involved in the regulation of homeotic(Hox) gene 
expression and in the early steps of X-chromosome 
inactivation [5, 6]. Mounting evidence demonstrated that 
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EZH2 function as an oncogene and a negative prognosis 
factor involving in carcinogenesis in many human cancer 
types [7-11]. EZH2 contains a SET domain with histone 
methyltransferases activity, which catalyses trimethylation 
of lysine 27 in histone 3 (H3K27me3) [12]. EZH2 and 
the other three core accessory proteins (EED, SUZ12, 
and RbAp46/48) induce chromatin compaction and 
consequently prevent transcription of target genes [12, 13]. 
In most cancer types, elevated EZH2 function 
has predominantly been associated with tumor cell 
proliferation, cell cycle and migration [14-17]. EZH2 
mediated tumor suppressor genes’ silencing contributes to 
cancer progression. P21, p16 and NLK are validated to be 
direct targets of EZH2 [14, 18]. In human HNSCC cells, 
loss of EZH2 partially interfered with proliferation and 
invasion ability in vitro and in vivo. However, whether and 
how targets EZH2 inducing cell apoptosis is still missing. 
Apoptosis is a cellular procedure that is regulated 
by different regulatory molecules and the dysfunction 
of apoptosis results in various pathological disorders in 
humans such as cancers [19]. Escape from apoptosis is a 
key attribute of tumor cells and facilitates proliferation. 
The mitochondrial dependent cell death pathway 
integrates stress and survival signaling to govern whether 
a cancer cell will live or die [20]. It is characterized by 
the loss of mitochondrial membrane potential(ΔΨm) 
[21]. Mitochondrial calcium uniporter (MCU), a 
notable mitochondrial Ca2+ uniporter complex, has 
been demonstrated to be regulated through its subunit 
mitochondrial calcium uptake 1(MICU1) in human models 
[22-24].
In the present work, we first analyzed EZH2 
expression in a Chinese HNSCC cohort and HNSCC 
cohort form TCGA, and we further identify inhibition 
of EZH2 inducing HNSCC cell apoptosis in cell lines in 
vitro and in a Cal27 derived tumor model. We determined 
that mitochondrial dependent apoptosis in HNSCC cell 
was significantly induced when EZH2 was depleted and 
targeting EZH2 might represent a powerful strategy for the 
development of novel therapies interfering with distinct 
aspects of HNSCC.
RESULTS
EZH2 was highly expressed in HNSCC and 
conferred to poor patient survival
First, we analyzed EZH2 expression in a Chinese 
HNSCC cohort of 97 cases and normal oral cavity 
mucosa samples of 16 cases by using IHC assay. 12 of 
Table 1: Correlation between EZH2 and clinical-pathologic characteristics of patients with HNSCC
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16 normal oral cavity mucosa samples showed negative 
staining of EZH2. In agree with previous studies, human 
HNSCC displayed positive expression of EZH2 in tumor 
cell nuclei (Figure 1A). There were 49 HNSCC samples 
showed positive expression of EZH2 and 48 negative 
(50.51%). No statistical significance of EZH2 expression 
was determined between groups with different age at 
diagnosis and sex status (Table1). HNSCC with larger 
tumor size ( > 2cm) showed a higher positive rate of EZH2 
comparing with the smaller tumor size group (≤2cm, χ2 = 
7.980, P = 0.006). Similarly, EZH2 expression of TNM 
stage IV HNSCC was higher than that of TNM stage I-III 
tumors (χ2 = 8.743, P = 0.037). Apart from tumor size and 
clinical stage, EZH2 was differently expressed among the 
HNSCC samples with different histological types. EZH2 
expression was lower in well or moderate differentiated 
HNSCC than in poorly differentiated tumors (χ2 = 11.587, 
P = 0.003) (Table 1). These data implied EZH2 is a 
potential marker with diagnosis potential in HNSCC.
Second, to further study the significance of high 
EZH2 expression for prognosis in HNSCC patients, we 
established four EZH2 status patient groups by using 
quantile based on RNAseq form The Cancer Genome 
Atlas (TCGA). Kaplan-Meier survival analysis showed 
that the patients with upper quantile EZH2 expression 
showed shorter survival comparing with the rest patients 
(P < 0.05; Figure1B). EZH2 expression of different tumor 
grades displayed obvious difference (P < 0.05; Figure 1C).
Figure 1: EZH2 was highly expressed in HNSCC and conferred to poor patient survival. A. Representative images of 
immunohistochemical staining of EZH2 from human HNSCC. B. TCGA data analysis indicated that upper quantile EZH2 expression 
showed shorter survival comparing with the rest patients (P < 0.05). C. EZH2 expression of different tumor grades displayed obvious 
difference, y axis showed the log10 RPKM of EZH2 in TCGA datasets. 
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Targeting EZH2 suppressed its function in 
HNSCC cells
Cal27 and SCC25 cells showed higher expression 
of EZH2, H3K27me3 and MICU1 comparing with 
Tb3.1, UM1 and Hep-2 cell lines (Figure 2A). To address 
EZH2’s role in HNSCC, we blocked EZH2 activity in 
human HNSCC by chemical inhibition using DZNep. 
Cell viability curve indicated that, comparing with Cal27 
cell (IC50 = 6μM), SCC25 (IC50 = 3μM) was more 
sensitive to DZNep (Figure 2B). DZNep treatment led to 
considerable reduction of EZH2, H3K27me3 and MICU1 
expression in a dose-dependent manner (Figure 2C). 
Moreover, we employed EZH2 siRNA (si-EZH2) to block 
EZH2, the results showed that the expression of EZH2 and 
MICU1 were decreased (Figure S2A).
EZH2 was required for growth of HNSCC in vitro
Since our previous report indicated that EZH2 
inhibition suppressed glioma cell growth by regulating 
cell cycle progression, we hypothesized that there was a 
similar phenomenon in HNSCC. We employed several in 
vitro assays to demonstrate the requirement of EZH2 for 
HNSCC growth. 
MTT assay indicated that, DZNep treated Cal27 and 
SCC25 cell showed significantly reduction of cell viability 
comparing with DMSO treated cells at 24h, 48h and 
72h (P < 0.05, Figure 3A, 3B), and the most significant 
reduction of cell viability is 48h after DZNep treatment. 
Flow-cytometry data revealed that significant G1 phase 
increase was observed in EZH2 treated Cal27 (1.16-
1.34 folds) and SCC25 (1.18-1.39 folds) cells (P < 0.05, 
Figure 3C, 3D). Clone formation assay indicated that, 15 
days after a single does-treatment of DZNep, the clones 
density of Cal27 reduced from (14.8 ± 2.6) to (5.3 ± 2.6) 
(per 100mm2) (P < 0.05), and the clones density of SCC25 
reduced from (14.5 ± 4.2) to (4.5 ± 1.3) (per 100mm2) (P 
Figure 2: DZNep suppressed EZH2 function in HNSCC cell. A. EZH2, MICU1 and H3K27me3 expression were determined by 
western blot analysis in five HNSCC cell lines. B. The cell viability curve of Cal27 and SCC25 cell lines. C. Western blot analysis of Cal27 
and SCC25 cells shows the expression of EZH2, MICU1 and H3K27me3 after treatment with DZNep at 48 h, with GAPDH and Histone 
3 serving as loading control. 
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< 0.05, Figure3E, 3F). The cell cycle dependent oncogene 
Cyclin D1 level was down-regulated while p16 and p21 
expression were up-regulated by EZH2 blockage (Figure 
3G). 
Targeting EZH2 induced apoptosis of HNSCC in 
vitro
Anti-apoptosis is the common feature of cancer 
progression. We employed Annexin V/PI assay to evaluate 
the anti-apoptosis role of DZNep or si-EZH2 in treating 
HNSCC. DZNEP induced early and latent phase of 
apoptosis in Cal27 (DMSO: 0.6%, DZNep (2μM: 9.5%, 
6μM: 20.2%), P < 0.05) and SCC25 (DMSO: 0.3%, 
DZNep (1μM: 5.6%, 3μM: 15.4%), P < 0.05, Figure 
4A) cell line, and si-EZH2 also induced early and latent 
phase of apoptosis in two cell lines. To assess the effect of 
EZH2 inhibition in inducing cell senescence, senescence-
related β-galactosidase staining is employed. In contrast 
to DMSO treated cells, DZNep treated Cal27 and SCC25 
cells displayed a 9- to 10-fold (P <  0.05) higher SA-β-Gal 
Figure 3: EZH2 was required for growth of HNSCC in vitro. A., B. Cal27 and SCC25 cells proliferation were significantly 
impaired after DZNep treatment for 48h as measured by MTT assay (* represent P < 0.05). C., D. Flow-cytometry was performed to 
examine the G1/S arrest effect in Cal27 and SCC25 cells after treatment with DZNep at 48h (P < 0.05). E., F. Reduction of clone formation 
ability in DZNep- treated Cal27 (6 μmol/L) and SCC25 (3μmol/L) cells (P < 0.05). G. Western blot analysis shows the expression of Cyclin 
D1, p16, p21 in both cells treated with DZNep (Cal27: 6μmol/L and SCC25: 3μmol/L) at 48h, with GAPDH as a loading control (P < 0.05).
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activity in both cell cultures (Figure 4B, 4C). Similarly, si-
EZH2 increased SA-β-Gal activity in two cell lines (Figure 
S2D, E). We then analyzed the changes in the levels of 
pro-apoptotic proteins BAX, and Cleaved caspase-3, and 
anti-apoptotic protein Bcl-2. The results indicated that 
Bcl-2 was decreased and BAX or Cleaved caspase-3 was 
increased by DZNep or si-EZH2 treatment in both cell 
lines (Figure 4D, S2F). 
Moreover, the loss of ΔΨm is an early event in 
apoptosis. ΔΨm was detected by JC-1 fluorescent probe. 
As shown in Figure 5A, when Cal27 and SCC25 cell were 
treated with DZNep for 24h, ΔΨm was drastically reduced 
respectively in both cell lines. We measured ΔΨm after 
Cal27 and SCC25 cell were transfected with si-EZH2, the 
result showed that si-EZH2 reduced ΔΨm in both cell lines 
(Figure S2C). Next we used Ca2+ indicator, Fluo 3-AM, to 
determine the free Ca2+ level induced by EZH2 inhibition. 
The results showed that DZNep treatment of Cal27 and 
SCC25 cell increased Ca2+ accumulation in cytoplasm 
(Figure 5B). More importantly, DZNep treatment inhibited 
the cyto-Ca2+regulator MICU1 expression in both cell 
lines. MCU expression showed no significant changes by 
DZNep treatment. By contrast, Cytochrome c expression 
was increased dramatically (Figure 5C).
Thirdly, we investigated the correlations between 
EZH2 and other apoptosis related genes by using linear 
regression association test in HNSCC dataset published by 
TCGA. A gene with p-value less than 0.05 was considered 
to be significantly EZH2-associated. We observed that 
EZH2 was positively associated with CBARA1 (MICU1), 
BCL2 and MKI67, and negatively associated with CASP4, 
CCND1 and CDKN1A in the term of expression (P < 0.05, 
see Figure S1A-F).
MICU1 regulated HNSCC cell apoptosis in vitro
Next, we employed a MICU1 shRNA (shMICU1) 
vector to further validate the role of targeting EZH2/
MICU1 in regulating cell apoptosis in HNSCC cells. We 
first analyzed the MICU1 expression changes induced by 
Figure 4: Targeting EZH2 induced apoptosis of HNSCC in vitro. A. The percentages of apoptotic cells were significantly 
increased by DZNep treatment in a dose dependent (P < 0.05). B., C. SA-β-gal staining positive cells were determined and compared after 
Cal27 and SCC25 cells were treated with DZNep (Cal27: 6μmol/L and SCC25: 3μmol/L) or DMSO for 48h (P < 0.05). D. Western blot 
analysis shows the expression of BAX, Bcl-2, Cleaved caspase-3 in both cells treated with DZNep (Cal27: 6μmol/L and SCC25: 3μmol/L) 
at 48h, with GAPDH as a loading control (P < 0.05). 
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shMICU1 in both cell lines, and shMICU1-3 treatment 
showed the robust effect in inhibiting MICU1 expression 
(Figure 6A). Thus, we selected shMICU1-3 for further 
research usage. The Annexin V/PI assay results indicated 
a significant increase in cell apoptosis with the depletion 
of MICU1, the ratio of early apoptotic cell increased 
from 0.28% to 8.75% in Cal27 and 0.18% to 4.66% in 
SCC25 (P < 0.05, Figure 6B). Moreover, we combined 
MICU1 expression vector (GV230-MICU1) with DZNEP 
treated two cell lines, the ratio of early apoptotic cell is 
4.7% in Cal27 and 2.26% in SCC25 (P < 0.05, Figure 
6B). As shown in Figure 6C, when Cal27 and SCC25 cell 
were treated with shMICU1 for 48h, ΔΨm was drastically 
reduced respectively in both cell lines and Ca2+ indicator 
suggested free Ca2+ level induced by MICU1 targeting 
(Figure 6C, 6D). Western blot analysis showed that Bcl-
2 was decreased and BAX or Cleaved caspase-3 was 
increased by shMICU1 treatment in both cell lines (Figure 
6E). Moreover, we introduced GV230-MICU1 into Hep-2 
cell that had a low endogenous MICU1 expression level as 
shown in Figure 2A. Early apoptosis rate decreased from 
3.6% to 0.8% in Hep-2 (Figure 6F). Western blot analysis 
showed that anti-apoptotic protein MICU1 and Bcl-2 
was increased (Figure 6G). These data provide important 
evidence that MICU1 play an important role in EZH2- 
regulated cell death pathway.
Targeting EZH2 inhibited HNSCC tumor growth 
and induced apoptosis in vivo
To better illustrate the role of EZH2 in HNSCC 
tumor growth, we established HNSCC xenograft tumor 
model using Cal27 cell lines. Comparing with DMSO 
treated tumors, DZNep treated tumors showed significant 
reduction of tumor volume and weight (P < 0.05, Figure 
Figure 5: Targeting EZH2 affected mitochondrial membrane potential balance. A. Mitochondrial membrane potentials 
were reduced by DZNep (Cal27: 6μmol/L and SCC25: 3μmol/L), the evident in confocal image soft the fluorescent dye JC-1 in Cal27 
and SCC25 cell lines. B. Ca2+ indicator to determine the free Ca2+ level induced by DZNep (Cal27: 6μmol/L and SCC25: 3μmol/L). C. 
Western blot analysis shows the expression of Cytochrome c, MICU1, MCU in both cells treated with DZNep (Cal27: 6μmol/L and SCC25: 
3μmol/L) at 48h, with GAPDH as a loading control (P < 0.05). 
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7A-7C). TUNEL assay was used to determine the DNA 
fragmentation, which was the hallmark of apoptotic cells. 
The results indicated that DZNep treatment induced more 
apoptotic nuclei than in DMSO treated Cal27 xenograft 
tumors (Figure 7D). Strikingly, HE staining showed 
morphological changes in Cal27 tumors by DZNep 
treatment. For example, in DZNep treated group, Cal27 
tumors displayed less mitotic figures, chromosome 
staining and cell density (Figure 7E). Most importantly, 
comparable to controlled tumors, DZNep treatment was 
sufficient to attenuate cell proliferation protein Ki-67, 
cyto-Ca2+ regulator MICU1, anti-apoptotic protein Bcl-
2 as well as EZH2, and to increase Cleaved caspase-3 
expression in vivo (Figure 7E). 
DISCUSSION
In this study, we demonstrate over-expressed EZH2 
to be a key target with diagnosis and therapeutic potential 
in HNSCC. Analysis of HNSCC TCGA dataset suggested 
EZH2 activity might influence the downstream apoptosis 
related genes. Importantly, inhibition of EZH2 with 
chemical synthesized compound DZNep, induced loss 
of ΔΨm and cell apoptosis in HNSCC cell in vitro and 
in vivo. We also reported that EZH2 inhibition induced 
MICU1 inactivation and cyto-Ca2+ accumulation which 
might be the underling mechanism. 
Elevated EZH2 levels often are directly correlated 
with advanced metastatic stages of cancer progression 
and poor prognosis. In glioma and renal cell carcinomas, 
increased EZH2 expression was associated with tumor 
grade and high expression of EZH2 was determined to be a 
Figure 6: MICU1 regulated HNSCC cell apoptosis in vitro. A. MICU1 expression changes induced by shMICU1 in both cell 
lines. B.: Flow cytometry was performed to examine the apoptosis of Cal27 and SCC25 cells after transfection with ShMICU1 or GV230-
MICU1 combining with DZNep (Cal27: 6μmol/L and SCC25: 3μmol/L). C. Ca2+ indicator to determine the free Ca2+ level induced by 
MICU1 inhibition. D. Mitochondrial membrane potentials were reduced by MICU1 inhibition, the evident in confocal image soft the 
fluorescent dye JC-1 in Cal27 and SCC25 cell lines. E. Western blot analysis shows the expression of BAX, Bcl-2, Cleaved caspase-3 in 
both cells treated with ShMICU1 at 48h, with GAPDH as a loading control (P < 0.05). F. Flow-cytometry was performed to examine the 
apoptosis of Hep-2 after transfection with GV230-MICU1. G. Western blot analysis shows the expression of MICU1, Bcl-2 in Hep-2 cell 
treated with GV230-MICU1 at 48h, with GAPDH as a loading control (P < 0.05).
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strong and independent predictor of short overall survival 
[16, 25]. Comparing with normal mucosa or adjacent 
normal tissue, EZH2 was overexpressed in 50-60% of 
HNSCC tissues and contributed to tumor differentiation 
status [26, 27]. Additionally, EZH2 has been found to 
initiate oral leukoplakia malignant transformation and 
epithelial-mesenchymal transition in HNSCC [28]. In 
the present work, we analyzed the EZH2 expression in 
TCGA dataset, and we found the higher expression of 
EZH2 might predict shorter overall survival of HNSCC 
patients. And examination of HNSCC specimens showed 
EZH2 expression was associated with tumor size, 
histological differentiation and clinical stage. Our data 
further confirmed EZH2 was a robust prognostic factor for 
human HNSCC and a biomarker for identifying HNSCC 
molecular subtypes. 
EZH2 is required for tumor progression in 
H3K27me3 dependent manner, and this can be blocked 
by EZH2 inhibitors, like GSK126 or EPZ-6438 [29]. 
In tongue cancer and glioblastoma, EZH2 depletion 
suppressed tumor growth by arresting cell cycle 
progression [17, 30]. Our data suggested that, we used 
pharmacological EZH2 inhibition via DZNep, which 
causes proteosomal degradation of EZH2 [31, 32]. DZNep 
treatment effectively reduced EZH2 and H3K27me3 
expression in both cell lines. Of note, EZH2 inhibition 
Figure 7: Targeting EZH2 inhibited HNSCC tumor growth and induced apoptosis in vivo. A.-C. Tumor volume and 
weight of DMSO or DZNep-treated animals was measured. D. TUNEL assay showed an induced apoptotic nucleus (green) in DZNep-
treated Cal27 tumors (magnification: x1000). E.: Representative images of immunohistochemical staining of EZH2, MICU1, MCU, Ki67, 
CyclinD1, Bcl-2, BAX and Cleaved caspase-3 in tissue from mice with tumors derived from Cal27 cells treated with DMSO or DZNep, 
and HE staining was used to examine morphological changes (magnification: 200x).
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impairs tumor cell proliferation ability, cell cycle 
progression and anti-apoptisis potential in both cell lines 
and this suppressed Cal27 derived tumors’ growth in a 
xenograft model. These data fully illustrated that EZH2 
serves as a target with therapeutic potential in HNSCC.
To address the mechanism through which EZH2 
inhibition effecting tumor cell apoptosis, we found that 
HNSCC cell showed spatially increase of cyto-Ca2+ and 
loss of ΔΨm was induced by DZNep treatment. A well-
established notion that MCU is a highly selective channel 
with Ca2+ transmission capability and MICU1 has been 
shown to regulate the mitochondrial Ca2+uniporter, which 
pumps cytosolic Ca2+ into the mitochondria [33]. In the 
absence of MICU1, mitochondria become constitutively 
loaded with Ca2+, triggering excessive reactive oxygen 
species generation and sensitivity to apoptotic stress [23, 
34]. Although the underlying mechanisms by which EZH2 
regulates MICU1 to prevent HNSCC cell apoptosis is not 
entirely clear, our data showed inhibiting EZH2 triggers 
cyto-Ca2+ accumulation, loss of ΔΨm, G1 phase cell cycle 
arrest and changes on proteins of mitochondrial related 
cell death pathway. More importantly, gain or loss function 
assays suggested that targeting MICU1 could compensate 
EZH2’s effect on regulating tumor cell apoptosis.
On the basis of increasing integrated research and 
experimental evidence, it is now fully elucidated that 
EZH2 plays a central role in cancer transformation, and 
its overexpression is associated with tumor cell anti-
apoptosis, invasiveness, chemo-resistance in human 
cancers including HNSCC. Further, pharmacological 
inhibition of EZH2 by using DZNep, GSK503 [35], 
GSK126 [36] and etc provided a novel approach in 
treating human epithelium cancers. Accordingly, our study 
reveals that targeting EZH2 might be a promising strategy 
for future therapies of human HNSCC patients.
MATERIALS AND METHODS
HNSCC samples and Immunohistochemistry for 
EZH2
A total of 97 HNSCC tumor samples from radical 
resection were randomly collected at Tianjin Medical 
University Cancer Institute & Hospital during January 
2009 to December 2012. The demographic and clinical 
data was collected from electric records. All the tissue 
samples were used for EZH2 expression examination. All 
samples were collected with informed consent according 
to the Human Tissue Sample Usage Guidelines of the 
Tianjin Medical University Medical Ethnic Committee. 
Immunohistochemistry staining for EZH2 (Cell 
Signaling Technology) of 97 HNSCC samples from Tianjin 
Medical University Cancer Institute & Hospital was 
performed on formalin-fixed, paraffin-embedded tissue 
sections, according to the manufacturer’s instructions. 
Each stained slide was jointly scored by 2 pathologists 
blinded to the clinical information. For statistical 
analysis, positive expression of EZH2 was defined as > 
10% of positive-stained cells in the tumor. Two blinded 
pathologists independently evaluated the slides. In case of 
a discrepancy, the 2 observers simultaneously reviewed 
the slides to achieve a consensus.
HNSCC mRNA datasets and analysis
Transcriptom expression datasets and the 
corresponding clinical information were downloaded 
from websites of The Cancer Genome Atlas (http://
cancergenome.nih.gov).Total 508samples were available 
for this analysis. RPKM were calculated from RNA-seq 
read counts of each mRNA and log transformations were 
performed to increase the normality. We applied linear 
regression study the gene co-expression and ordinal data 
analysis to study the association between EZH2 expression 
and tumor stage information. With survival duration data 
from TCGA, we estimated Kaplan-Meier survival curves 
of low-risk and high risk groups separated by the mean of 
EZH2 expression. Also the Log-rank test were performed 
to test the significance of difference of survival curves 
between these two groups. Data manipulation, statistical 
analysis and visualization were accomplished using R 
3.0.2.
Cell lines and culture conditions
Human HNSCC cell line Hep-2 was purchased from 
the Institute of Basic Medical Sciences, Chinese Academy 
of Medical Sciences. Tb3.1 cell line was a gift from the 
Ninth People’s Hospital Shanghai Jiao Tong University. 
Cal27, SCC25, UM1 cell lines were was kindly provided 
by Prof. JinsongHou of Guanghua School of Stomatology, 
Hospital of Stomatology, SunYat-sen University. The cell 
lines were maintained in MEM, DMEM or RPMI-1640 
(Thermo Scientific) supplemented with 10% fetal bovine 
serum (FBS, Thermo Scientific) with 5% CO2 at 37℃.
Drug treatments
For EZH2 inhibition, Cal27 and SCC25 cells were 
treated with 3-Deazaneplanocin A (DZNep) (2 or 6μmol/L 
for Cal27 cell, 1or 3μmol/L for SCC25 cell) (Merck 
Millipore) dissolved in dimethyl sulfoxide (DMSO, 
Sigma-Aldrich) for 48 hours.
SiRNA, ShRNA and vector transfection
SiRNA (GeneChem) was used to knockdown 
EZH2 expression in Cal27 and SCC25 cell lines, using 
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Lipofectamine 3000 reagent as the manufacturer’s 
instructions (Life Technology). The final concentration of 
EZH2 siRNA is 75nM. 48h after transfection the Cal27 
and SCC25 cell lines were harvest for research usage.
ShRNA (GeneChem) were used to knockdown 
MICU1 expression in Cal27 and SCC25 cell lines. 5μg 
shRNA was transfected to cells, using Lipofectamine 
3000 reagent as the manufacturer’s instructions (Life 
Technology). 
5μg MICU1 full-length expression vector 
(GV230-MICU1, GeneChem) was transfected to 2×106 
HNSCC cells by using Lipofectamine3000 reagent as 
the manufacturer’s instructions (Life Technology). The 
GV230 empty vector (GV230-NC, GeneChem) was used 
as the control plasmid. 48h after transfection, the cells 
were collected for apoptosis examination and whole cell 
lysate were collected for Western blot analysis.
Cell experiments in vitro
For apoptosis analysis by flow cytometry, 
DMSO or DZNep treated Cal27 and SCC25 cells were 
digested with trypsin (Gibico) and resuspended as 
single-cell suspension. Double staining with fluorescein 
isothiocyanate (FITC)-Annexin V and propidium iodide 
(PI) was completed using a FITC Annexin V Apoptosis 
Detection Kit (Keygen) according to the instructions 
provided by the manufacturer. Apoptosis was measured 
using flow cytometry.
For cell cycle distribution analysis by flow 
cytometry, after DMSO or DZNep treated Cal27 and 
SCC25 cells, the cells were trypsinized, fixed in 70% 
ethanol, washed once with PBS, and then labeled with 
propidium iodide (Keygen) in the presence of RNase 
A (Sigma-Aldrich) for 30 min in the dark. Cell cycle 
distribution was measured using flow cytometry.
For colony forming assay, 1,000 cells treated with 
DZNep or DMSO were seeded into 6-well plates and 
allowed to grow for 14 days. The cells were then fixed 
and stained with crystal violet. The colonies were further 
visualized under an invert microscope and photographed. 
Colonies numbers were counted from five different fields 
per 100mm2.
SA-β-gal staining (Beyotime Biotechnology) was 
performed following the supplier’s instructions. SA-β-gal 
positive cells were stained in blue. Total 500 cells from 
five different vision fields per section were counted under 
a pathology light microscope (Olympus) at 200×. All of 
the stained sections were examined by two independent 
observers.
JC-1 probe (Beyotime Biotechnology) was 
employed to measure mitochondrial depolarization. 
Briefly, Cells cultured in confocal capsule after indicated 
treatments were incubated with JC-1 staining solution 
at 37℃ for 20 min and rinsed twice with PBS. MMP 
were monitored by determining the relative amounts 
of dual emissions from mitochondrial JC-1 monomers 
or aggregates using FV-1000 laser scanning confocal 
biological microscopes (Olympus) under Argon-ion 
488 nm and 546 nm laser excitation. Mitochondrial 
depolarization is indicated by an increase in the green/red 
fluorescence intensity ratio.
Ca2+ indicator Fluo-3/AM was used to detect the 
intracellular Ca2+. After 24 h, the treated cells and the 
control cells, rinsed twice with PBS, were loaded with 
theFluo-3/AM (5μM) and continuously cultured at 37℃ 
for 60 min, at 5% CO2 incubator. The labeled cells were 
washed with PBS to remove the unloaded Fluo-3/AM. 
After cells were loaded with the fluorescence probe, 
changes in intracellular Ca2+of individual cells were 
measured using a digital imaging system equipped with 
a laser confocal scanning microscope (Olympus) with an 
excitation wavelength of 488 nm.
Western blot analysis was employed to assay 
protein expression. Total protein is extracted from 
DZNEP/shMICU1 treated HNSCC cells. The protein 
samples were resolved by SDS-PAGE and transferred 
onto PVDF membranes (Roche). The membranes were 
then incubated with the following antibodies: EZH2, 
MICU1, p16, p21, CyclinD1 and Cleaved caspase-3 
(Cell Signaling Technology), MCU and Cytochrome c 
(Abcam), Bcl-2 and BAX (Zhongshan Biotechnology), 
H3K27me3 (Signalway Antibody). GAPDH (Zhongshan 
Biotechnology) or Histone 3 (Cell Signaling Technology) 
was used as an internal control.
Cal27 tumor model study
Animal experiments were carried out using BALB/
c-A nude mice at 4 weeks of age, which were purchased 
from Vital River Laboratories China. All experimental 
animals were injected subcutaneously on the right groin 
region with 2×10 6 Cal27 cells. Twenty days later, tumors 
were formed, these mice were separated into two groups 
(8 mice per group), randomly. The DMSO group, the 
DZNep group (0.07 mg/kg dissolved in DMSO) [10].The 
mice received an injection into the tumor every three days, 
and the size of tumor and mice weights were measured 
by calipers and electronic weighing meter. Tumor volume 
was calculated as follows: volume = a*b2/2. Tumor 
weights were also measured on tumor samples harvested.
TUNEL assay
The cell apoptosis of the tumor samples was 
measured by TUNEL assay using an in situ cell death kit 
(Roche) by following the manufacture’s protocol. The cell 
nucleuses were counterstained by DAPI (Sigma) reagent. 
Positive cells were visualized by FV-1000 laser scanning 
confocal biological microscopes (Olympus).
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Immunohistochemistry (IHC)
The paraffin-embedded tissue sections were 
used for examination of EZH2, MICU1, CyclinD1and 
Cleaved caspase-3 (Cell Signaling Technology), MCU 
(Abcam), Bcl-2, BAX, Ki-67 (Zhongshan Biotechnology) 
expressions. For IHC assay, sections were incubated 
with primary antibodies (1:100 dilutions) overnight at 
4˚C, followed by a biotin-labeled secondary antibody 
(1:100 dilutions) (Zhongshan Biotechnology) for 40 min 
at 37 ˚C. Sections were incubated with ABC-peroxidase 
anddiaminobenzidine (DAB) (Zhongshan Biotechnology), 
counterstained with hematoxylin and visualized using 
light microscopy.
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